Histogenics Corporation Stock Price, News & Analysis (NASDAQ:HSGX)

$1.97 -0.02 (-1.01 %)
(As of 11/21/2017 04:00 PM ET)
Previous Close$1.99
Today's Range$1.91 - $2.06
52-Week Range$1.45 - $2.40
Volume40,671 shs
Average Volume137,565 shs
Market Capitalization$48.62 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Histogenics Corporation (NASDAQ:HSGX)

Histogenics Corporation logoHistogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company's product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. NeoCart is a cartilage-like implant created using a patient's own cartilage cells through a series of tissue engineering processes. The patient's cells are separated from a tissue biopsy specimen extracted from the patient and multiplied in its laboratory. The cells are then infused into its scaffold that provides structure for the developing implant. Before NeoCart is implanted in a patient, the cell- and scaffold construct undergoes a bioengineering process in the Company's Tissue Engineering Processor (TEP). The Company has operations in the United States and Israel.


Industry, Sector and Symbol:
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Sector: Healthcare
  • Symbol: NASDAQ:HSGX
  • CUSIP: N/A
  • Web: www.histogenics.com
Debt:
  • Current Ratio: 4.42%
  • Quick Ratio: 4.42%
Sales & Book Value:
  • Annual Sales: N/A
  • Price / Sales: N/A
  • Book Value: $0.85 per share
  • Price / Book: 2.32
Profitability:
  • Trailing EPS: ($0.22)
  • Net Income: $-16,200,000.00
  • Return on Equity: -658.91%
  • Return on Assets: -106.38%
Misc:
  • Employees: 47
  • Outstanding Shares: 24,070,000
 

Frequently Asked Questions for Histogenics Corporation (NASDAQ:HSGX)

What is Histogenics Corporation's stock symbol?

Histogenics Corporation trades on the NASDAQ under the ticker symbol "HSGX."

How were Histogenics Corporation's earnings last quarter?

Histogenics Corporation (NASDAQ:HSGX) released its quarterly earnings results on Thursday, November, 9th. The biotechnology company reported ($0.23) earnings per share for the quarter, topping analysts' consensus estimates of ($0.30) by $0.07. View Histogenics Corporation's Earnings History.

When will Histogenics Corporation make its next earnings announcement?

Histogenics Corporation is scheduled to release their next quarterly earnings announcement on Thursday, March, 15th 2018. View Earnings Estimates for Histogenics Corporation.

Where is Histogenics Corporation's stock going? Where will Histogenics Corporation's stock price be in 2017?

2 brokers have issued 1 year target prices for Histogenics Corporation's stock. Their forecasts range from $3.50 to $4.00. On average, they anticipate Histogenics Corporation's stock price to reach $3.75 in the next year. View Analyst Ratings for Histogenics Corporation.

What are Wall Street analysts saying about Histogenics Corporation stock?

Here are some recent quotes from research analysts about Histogenics Corporation stock:

  • 1. According to Zacks Investment Research, "Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment. The company is developing NeoCart(R) product to provide treatment in the orthopedic space. Histogenics Corporation is headquartered in Waltham, Massachusetts. " (11/15/2017)
  • 2. Canaccord Genuity analysts commented, "We highlight that momentum in patient enrollment accelerated in the Q2 with a record of 17 patients enrolled in the month of June and a total of 30 in the quarter. Furthermore, the company reiterated its expectations to deliver one-year data by the end of Q3/18, supporting its BLA filing shortly thereafter, and commercial launch of NeoCart as early as mid-2019. In Japan, management highlighted an agreement with the Japan PMDA regarding a regulatory pathway for the Japanese market, which will revolve around a small, 30- patient, one-year trial comparing NeoCart to microfracture treatment. The trial will be supplemented by US Phase 3 trial data, and Histogenics is currently exploring Japanese partnership opportunities to support the trial with hopes of finagling a partnership by YE/17. Of note, Histogenics hopes its Japanese partnership will provide the company with additional capital. We are encouraged by the progress in Japan and anticipate the geography could be a meaningful market for Histogenics’ long-term success. Investment highlights Reiterated expectations to deliver one-year NeoCart Phase 3 data by the end of Q3/18, supporting BLA filing shortly thereafter, and commercial launch of NeoCart in H2/19. Strengthened commercial management team with the appointment of Donald Haut, PhD as chief business officer. Dr." (8/11/2017)

Who are some of Histogenics Corporation's key competitors?

Who are Histogenics Corporation's key executives?

Histogenics Corporation's management team includes the folowing people:

  • Garheng Kong M.D. Ph.D., Independent Chairman of the Board (Age 41)
  • Adam Gridley, President, Chief Executive Officer, Director (Age 45)
  • Jonathan I. Lieber, Chief Financial Officer (Age 48)
  • Stephen Richard Kennedy, Chief Operating Officer, Executive Vice President (Age 60)
  • Joshua J. Baltzell, Independent Director (Age 47)
  • David N. Gill, Independent Director (Age 62)
  • John H. Johnson, Independent Director (Age 59)
  • Michael Lewis, Independent Director (Age 58)
  • Kevin L. Rakin, Independent Director (Age 57)

When did Histogenics Corporation IPO?

(HSGX) raised $60 million in an initial public offering (IPO) on Wednesday, December 3rd 2014. The company issued 4,300,000 shares at $13.00-$15.00 per share. Cowen and Company, Needham & Company and Canaccord Genuity acted as the underwriters for the IPO and BTIG was co-manager.

How do I buy Histogenics Corporation stock?

Shares of Histogenics Corporation can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Histogenics Corporation's stock price today?

One share of Histogenics Corporation stock can currently be purchased for approximately $1.97.

How big of a company is Histogenics Corporation?

Histogenics Corporation has a market capitalization of $48.62 million. The biotechnology company earns $-16,200,000.00 in net income (profit) each year or ($0.22) on an earnings per share basis. Histogenics Corporation employs 47 workers across the globe.

How can I contact Histogenics Corporation?

Histogenics Corporation's mailing address is 830 Winter St, WALTHAM, MA 02451-1477, United States. The biotechnology company can be reached via phone at +1-781-4577900 or via email at [email protected]


MarketBeat Community Rating for Histogenics Corporation (NASDAQ HSGX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  133 (Vote Outperform)
Underperform Votes:  85 (Vote Underperform)
Total Votes:  218
MarketBeat's community ratings are surveys of what our community members think about Histogenics Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Histogenics Corporation (NASDAQ:HSGX)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 2 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.75 (90.36% upside)

Consensus Price Target History for Histogenics Corporation (NASDAQ:HSGX)

Price Target History for Histogenics Corporation (NASDAQ:HSGX)

Analysts' Ratings History for Histogenics Corporation (NASDAQ:HSGX)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/21/2017HC WainwrightReiterated RatingBuy$3.50N/AView Rating Details
8/11/2017Canaccord GenuityReiterated RatingBuy$4.00LowView Rating Details
9/19/2016Needham & Company LLCBoost Price TargetBuy$8.00 -> $11.00N/AView Rating Details
9/7/2016William BlairDowngradeOutperform -> Market PerformN/AView Rating Details
8/11/2016BTIG ResearchUpgradeNeutral -> Buy$3.50N/AView Rating Details
(Data available from 11/21/2015 forward)

Earnings

Earnings History and Estimates Chart for Histogenics Corporation (NASDAQ:HSGX)

Earnings by Quarter for Histogenics Corporation (NASDAQ:HSGX)

Earnings History by Quarter for Histogenics Corporation (NASDAQ HSGX)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/15/2018        
11/9/2017Q3 2017($0.30)($0.23)ViewN/AView Earnings Details
8/10/2017Q2 2017($0.31)($0.25)ViewN/AView Earnings Details
5/11/2017Q1 2017($0.34)($0.27)ViewN/AView Earnings Details
3/16/2017Q4 2016($0.47)($1.60)ViewN/AView Earnings Details
11/10/2016Q316($0.62)($0.70)ViewListenView Earnings Details
8/11/2016Q216($0.60)($0.61)ViewListenView Earnings Details
5/12/2016Q116($0.59)($0.60)ViewListenView Earnings Details
3/10/2016Q415($0.59)($0.63)ViewListenView Earnings Details
11/12/2015Q315($0.47)($0.61)ViewListenView Earnings Details
8/12/2015Q215($0.49)($0.58)ViewListenView Earnings Details
5/14/2015Q115($1.34)($0.60)ViewListenView Earnings Details
2/26/2015Q414$0.66$0.54ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Histogenics Corporation (NASDAQ:HSGX)
Current Year EPS Consensus Estimate: $-1.07 EPS
Next Year EPS Consensus Estimate: $-0.59 EPS

Dividends

Dividend History for Histogenics Corporation (NASDAQ:HSGX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Histogenics Corporation (NASDAQ HSGX)

Insider Ownership Percentage: 23.80%
Institutional Ownership Percentage: 47.12%
Insider Trades by Quarter for Histogenics Corporation (NASDAQ:HSGX)
Insider Trades by Quarter for Histogenics Corporation (NASDAQ:HSGX)

Insider Trades by Quarter for Histogenics Corporation (NASDAQ HSGX)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/16/2017David N GillDirectorBuy3,000$1.81$5,430.00View SEC Filing  
5/16/2017David N GillDirectorBuy3,000$1.68$5,040.00View SEC Filing  
12/15/2016David N GillDirectorBuy3,000$1.65$4,950.00View SEC Filing  
12/9/2016David N GillDirectorBuy5,000$1.92$9,600.00View SEC Filing  
12/2/2016Jonathan I LieberCFOBuy5,000$1.95$9,750.00View SEC Filing  
12/1/2016Adam GridleyInsiderBuy5,000$2.01$10,050.00View SEC Filing  
9/29/2016Split Rock Partners Ii, LpMajor ShareholderBuy276,801$2.25$622,802.25View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Histogenics Corporation (NASDAQ HSGX)

Source:
DateHeadline
Histogenics Corporation (HSGX) Rating Reiterated by HC WainwrightHistogenics Corporation (HSGX) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - November 21 at 4:41 PM
Analyzing Histogenics Corporation (HSGX) and Innocoll Holdings PLC (INNL)Analyzing Histogenics Corporation (HSGX) and Innocoll Holdings PLC (INNL)
www.americanbankingnews.com - November 18 at 5:20 PM
Histogenics Corporation Announces Third Quarter 2017 Financial and Operating ResultsHistogenics Corporation Announces Third Quarter 2017 Financial and Operating Results
finance.yahoo.com - November 11 at 9:51 AM
Histogenics Corporation (HSGX) Releases  Earnings Results, Beats Expectations By $0.07 EPSHistogenics Corporation (HSGX) Releases Earnings Results, Beats Expectations By $0.07 EPS
www.americanbankingnews.com - November 10 at 7:32 PM
Histogenics Corporation (HSGX) & Its Peers Critical AnalysisHistogenics Corporation (HSGX) & Its Peers Critical Analysis
www.americanbankingnews.com - November 8 at 11:58 AM
Histogenics Corporation (HSGX) to Release Quarterly Earnings on ThursdayHistogenics Corporation (HSGX) to Release Quarterly Earnings on Thursday
www.americanbankingnews.com - November 2 at 1:28 AM
Histogenics Corporation (HSGX): Time For A Financial Health CheckHistogenics Corporation (HSGX): Time For A Financial Health Check
finance.yahoo.com - October 28 at 6:42 AM
Histogenics Corporation to Report Third Quarter 2017 Financial Results on November 9, 2017Histogenics Corporation to Report Third Quarter 2017 Financial Results on November 9, 2017
finance.yahoo.com - October 26 at 11:47 AM
Zacks: Brokerages Expect Histogenics Corporation (HSGX) Will Announce Earnings of -$0.30 Per ShareZacks: Brokerages Expect Histogenics Corporation (HSGX) Will Announce Earnings of -$0.30 Per Share
www.americanbankingnews.com - October 19 at 10:30 PM
Histogenics Corporation (HSGX) vs. The Competition Critical ReviewHistogenics Corporation (HSGX) vs. The Competition Critical Review
www.americanbankingnews.com - October 19 at 2:10 AM
Zacks Investment Research Lowers Histogenics Corporation (HSGX) to HoldZacks Investment Research Lowers Histogenics Corporation (HSGX) to Hold
www.americanbankingnews.com - October 17 at 12:34 AM
Histogenics Corporation Promotes Stephen Kennedy to Executive Vice President & Chief Operating OfficerHistogenics Corporation Promotes Stephen Kennedy to Executive Vice President & Chief Operating Officer
finance.yahoo.com - October 13 at 12:08 AM
Histogenics Corporation (HSGX) Presents At Cell & Gene Meeting On The Mesa - SlideshowHistogenics Corporation (HSGX) Presents At Cell & Gene Meeting On The Mesa - Slideshow
seekingalpha.com - October 6 at 8:07 PM
Critical Survey: Histogenics Corporation (HSGX) vs. Theravance Biopharma (TBPH)Critical Survey: Histogenics Corporation (HSGX) vs. Theravance Biopharma (TBPH)
www.americanbankingnews.com - October 5 at 9:46 AM
Histogenics Announces Publication of Additional Biomechanical Data From Human Engineered Cartilage TestingHistogenics Announces Publication of Additional Biomechanical Data From Human Engineered Cartilage Testing
finance.yahoo.com - October 2 at 6:32 PM
Histogenics Corporation to Present at the 2017 Cell & Gene Meeting on the MesaHistogenics Corporation to Present at the 2017 Cell & Gene Meeting on the Mesa
feeds.benzinga.com - September 26 at 9:35 AM
How Should You Think About Histogenics Corporation’s (HSGX) Risks?How Should You Think About Histogenics Corporation’s (HSGX) Risks?
finance.yahoo.com - September 14 at 6:10 AM
Histogenics Corporation (HSGX) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - SlideshowHistogenics Corporation (HSGX) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 12 at 11:50 PM
Histogenics (HSGX) Presents At Bairds 2017 Global Healthcare Conference - SlideshowHistogenics (HSGX) Presents At Baird's 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - September 10 at 12:03 AM
Histogenics Corporation (HSGX) Receives Consensus Recommendation of "Hold" from AnalystsHistogenics Corporation (HSGX) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - August 23 at 12:30 AM
Histogenics Corporation (HSGX) Given a $4.00 Price Target at HC WainwrightHistogenics Corporation (HSGX) Given a $4.00 Price Target at HC Wainwright
www.americanbankingnews.com - August 13 at 3:32 PM
Edited Transcript of HSGX earnings conference call or presentation 10-Aug-17 12:30pm GMTEdited Transcript of HSGX earnings conference call or presentation 10-Aug-17 12:30pm GMT
finance.yahoo.com - August 11 at 8:04 PM
Histogenics Corporations (HSGX) Buy Rating Reaffirmed at Canaccord GenuityHistogenics Corporation's (HSGX) Buy Rating Reaffirmed at Canaccord Genuity
www.americanbankingnews.com - August 11 at 4:48 PM
Histogenics Corporation Announces Second Quarter 2017 Financial and Operating ResultsHistogenics Corporation Announces Second Quarter 2017 Financial and Operating Results
www.nasdaq.com - August 11 at 2:38 AM
Histogenics Corporations (HSGX) CEO Adam Gridley on Q2 2017 Results - Earnings Call TranscriptHistogenics Corporation's (HSGX) CEO Adam Gridley on Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 11 at 2:38 AM
Histogenics reports 2Q lossHistogenics reports 2Q loss
finance.yahoo.com - August 11 at 2:38 AM
Histogenics Corporation (HSGX) Releases Quarterly  Earnings Results, Beats Expectations By $0.06 EPSHistogenics Corporation (HSGX) Releases Quarterly Earnings Results, Beats Expectations By $0.06 EPS
www.americanbankingnews.com - August 10 at 7:46 PM
Histogenics Corporation (HSGX) Expected to Announce Earnings of -$0.31 Per ShareHistogenics Corporation (HSGX) Expected to Announce Earnings of -$0.31 Per Share
www.americanbankingnews.com - August 6 at 10:26 AM
Histogenics Corporation (NASDAQ:HSGX) Set to Announce Quarterly Earnings on ThursdayHistogenics Corporation (NASDAQ:HSGX) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - August 3 at 7:16 AM
Contrasting Histogenics Corporation (NASDAQ:HSGX) and Galena Biopharma (GALE)Contrasting Histogenics Corporation (NASDAQ:HSGX) and Galena Biopharma (GALE)
www.americanbankingnews.com - July 29 at 7:26 AM
Histogenics Corporation (HSGX) Given Consensus Recommendation of "Hold" by BrokeragesHistogenics Corporation (HSGX) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - July 29 at 12:43 AM
Histogenics Corporation to Announce Second Quarter 2017 Financial Results on August 10, 2017Histogenics Corporation to Announce Second Quarter 2017 Financial Results on August 10, 2017
finance.yahoo.com - July 27 at 8:12 PM
Histogenics Corporation to Present at the 37th Annual Canaccord Genuity Growth ConferenceHistogenics Corporation to Present at the 37th Annual Canaccord Genuity Growth Conference
finance.yahoo.com - July 26 at 3:58 PM
 Analysts Expect Histogenics Corporation (NASDAQ:HSGX) to Post -$0.31 EPS Analysts Expect Histogenics Corporation (NASDAQ:HSGX) to Post -$0.31 EPS
www.americanbankingnews.com - July 17 at 10:57 AM
Histogenics Announces Publication of Data From Collagen and Chondrocyte 3-D Bioprinting StudyHistogenics Announces Publication of Data From Collagen and Chondrocyte 3-D Bioprinting Study
finance.yahoo.com - July 11 at 11:12 PM
Histogenics Corporation (NASDAQ:HSGX) Given Consensus Recommendation of "Buy" by BrokeragesHistogenics Corporation (NASDAQ:HSGX) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 4 at 12:33 AM
Histogenics (HSGX) Completes Enrollment in Phase 3 Trial of Neocart to Treat Knee Cartilage DamageHistogenics (HSGX) Completes Enrollment in Phase 3 Trial of Neocart to Treat Knee Cartilage Damage
www.streetinsider.com - June 29 at 12:07 AM
Histogenics (HSGX) CEO Adam Gridley on Q1 2017 Results - Earnings Call TranscriptHistogenics' (HSGX) CEO Adam Gridley on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 6:21 PM
Histogenics (HSGX) Announces Agreement With Japan PMDA on Regulatory Pathway for NeoCartHistogenics (HSGX) Announces Agreement With Japan PMDA on Regulatory Pathway for NeoCart
www.streetinsider.com - May 8 at 5:26 PM
Histogenics Corporation (HSGX) Presents At 16th Annual Needham Healthcare Conference - SlideshowHistogenics Corporation (HSGX) Presents At 16th Annual Needham Healthcare Conference - Slideshow
seekingalpha.com - April 7 at 10:18 AM
HISTOGENICS CORP Files SEC form 8-K, Other EventsHISTOGENICS CORP Files SEC form 8-K, Other Events
biz.yahoo.com - March 27 at 5:22 PM
Histogenics Corporation Announces Financial and...Histogenics Corporation Announces Financial and...
www.benzinga.com - March 16 at 4:24 PM
Histogenics (HSGX) CEO Adam Gridley on Q4 2016 Results - Earnings Call TranscriptHistogenics' (HSGX) CEO Adam Gridley on Q4 2016 Results - Earnings Call Transcript
seekingalpha.com - March 16 at 4:24 PM
Histogenics Corporation Announces Financial and Operating Results for the Fourth Quarter and Year Ended December 31, 2016Histogenics Corporation Announces Financial and Operating Results for the Fourth Quarter and Year Ended December 31, 2016
us.rd.yahoo.com - March 16 at 4:24 PM
Q4 2016 Histogenics Corp Earnings Release - Before Market OpenQ4 2016 Histogenics Corp Earnings Release - Before Market Open
us.rd.yahoo.com - March 16 at 4:24 PM
Histogenics Announces Publication of Biomechanical and Structural Data From Human Engineered Cartilage TestingHistogenics Announces Publication of Biomechanical and Structural Data From Human Engineered Cartilage Testing
us.rd.yahoo.com - March 9 at 3:50 PM
8:36 am Histogenics announces the publication in the Journal of Orthopaedic Research of a peer-reviewed publication entitled Mechanical Properties and Structure-Function Relationships of Human Chondrocyte-Seeded Cartilage Constructs After I8:36 am Histogenics announces the publication in the Journal of Orthopaedic Research of a peer-reviewed publication entitled Mechanical Properties and Structure-Function Relationships of Human Chondrocyte-Seeded Cartilage Constructs After I
us.rd.yahoo.com - March 9 at 3:50 PM
Histogenics (HSGX) Announces Publication of MRI Data From NeoCart Phase 1, Phase 2Histogenics (HSGX) Announces Publication of MRI Data From NeoCart Phase 1, Phase 2
www.streetinsider.com - January 13 at 11:57 PM
HISTOGENICS CORP Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard;HISTOGENICS CORP Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard;
biz.yahoo.com - November 21 at 10:36 AM
Form 8-K HISTOGENICS CORP For: Nov 10Form 8-K HISTOGENICS CORP For: Nov 10
www.streetinsider.com - November 10 at 4:54 PM

Social Media

Financials

Chart

Histogenics Corporation (NASDAQ HSGX) Chart for Tuesday, November, 21, 2017
Loading chart…

This page was last updated on 11/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.